Hugh T. Reyburn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hugh T. Reyburn has a total of 189 co-authors. Here are the top co-authors by number of shared publications:
- Mar Valés-Gómez
Department of Immunology and Oncology, National Centre for Biotechnology, Spanish National Research Council (CNB-CSIC), Madrid, Spain
13 shared publications Gloria Esteso
Madrid
7 shared publicationsMar Valés-Gómez
Department of Immunology and Oncology, National Centre for Biotechnology, Spanish National Research Council (CNB-CSIC), Madrid, Spain
5 shared publicationsEduardo López-Granados
Department of Clinical Immunology, Hospital Universitario La Paz, Center for Biomedical Network Research on Rare Diseases (CIBERER U767), Lymphocyte PathophysiologyPathophysiology in Immunodeficienc
4 shared publicationsAlfonso Blázquez-Moreno
Department of Immunology and Oncology, National Centre for Biotechnology (CNB-CSIC), Madrid, Spain
3 shared publicationsAna Dopazo
Genomics Unit, Centro Nacional de Investigaciones Cardiovasculares (CNIC)
3 shared publications
Latest Publications
- Open Access
The HUSH Complex Dictates EBV-transformed B cell Sensitivity to NK Cell Surveillance Through Repression of NKG2A Ligand γ-Proto-cadherin
Summary: Natural Killer (NK) cells control Epstein-Barr virus (EBV), though how EBV+ B-cells escape NK surveillance to form tumors remains unknown. To gain insights, we performed a human genome-wide CRISPR-Cas9 screen in EBV-transformed lymphoblastoid cell lines (LCL). This revealed that the HUSH complex maintains LCL sensitivity to NK. HUSH knockout (KO) de-repressed LCL protocadherin gamma (PCDHG), typically expressed by neurons. PCDHG expression protected LCLs from NK and was necessary for HUSH KO-driven NK resistance. CRISPR analyses revealed NKG2A/CD94 as the PCDHG NK inhibitory counter-receptor, and NKG2A KO restored NK lysis of HUSH KO LCLs. HUSH perturbation impaired NK control of murine LCL xenografts in vivo. A subset of follicular lymphoma (FL) upregulate PCDHG, and PCDHG KO enhanced FL lysis by NK. Therefore, HUSH plays dual roles in foreign DNA surveillance and in support of NK, potentially as a neuronal ‘don’t kill me’ signal that can be exploited by transformed cells.
Open AccessThe HUSH Complex Dictates EBV-transformed B cell Sensitivity to NK Cell Surveillance Through Repression of NKG2A Ligand γ-Proto-cadherin
Summary: Natural Killer (NK) cells control Epstein-Barr virus (EBV), though how EBV+ B-cells escape NK surveillance to form tumors remains unknown. To gain insights, we performed a human genome-wide CRISPR-Cas9 screen in EBV-transformed lymphoblastoid cell lines (LCL). This revealed that the HUSH complex maintains LCL sensitivity to NK. HUSH knockout (KO) de-repressed LCL protocadherin gamma (PCDHG), typically expressed by neurons. PCDHG expression protected LCLs from NK and was necessary for HUSH KO-driven NK resistance. CRISPR analyses revealed NKG2A/CD94 as the PCDHG NK inhibitory counter-receptor, and NKG2A KO restored NK lysis of HUSH KO LCLs. HUSH perturbation impaired NK control of murine LCL xenografts in vivo. A subset of follicular lymphoma (FL) upregulate PCDHG, and PCDHG KO enhanced FL lysis by NK. Therefore, HUSH plays dual roles in foreign DNA surveillance and in support of NK, potentially as a neuronal ‘don’t kill me’ signal that can be exploited by transformed cells.
- Open Access
- 18 January 2026
- Published by Springer Nature in Research Square
A high-resolution, unbiased analysis of the cellular immune response to Epstein-Barr virus
More than 95% of humans are infected with Epstein-Barr virus (EBV), yet although EBV infection has been associated with inflammatory and autoimmune diseases, lymphoproliferative disorders, and several types of cancer, for the vast majority of infected people the infection is asymptomatic as EBV replication is controlled by the immune system. Immunity against this virus has been studied since the discovery of EBV in the 1960s, and although important insights have been made, no unbiased, global studies of immune responses to EBV in healthy seropositive subjects have been reported. Here we describe a novel protocol to study the cellular immune response to EBV, detecting lymphocytes that respond to EBV via analyses of proliferation or induced expression of activation markers and cytokines. Using this system we sequenced, for the first time at a single-cell level, the transcriptome of all cells capable of responding to EBV in healthy individuals and in patients with inborn errors of immunity (IEI) associated with susceptibility to EBV infection. Lymphocyte cytotoxicity appears to be crucial for the proper control of EBV-infection, while a proportionate T-regulatory cell response likely helps to avoid excessive immunity and immune pathology. We also show that γδ T cells expressing the TCR Vδ1 chain use various activating natural killer (NK) cell receptors to recognise and kill EBV-infected lymphoblastoid cell lines (LCLs) and thus could be a promising candidate for allogeneic cell therapy for EBV-associated lymphoproliferative disorders in patients with either primary or secondary immunodeficiencies.
- 18 January 2026
- Published by Springer Nature in Research Square
Open AccessA high-resolution, unbiased analysis of the cellular immune response to Epstein-Barr virus
More than 95% of humans are infected with Epstein-Barr virus (EBV), yet although EBV infection has been associated with inflammatory and autoimmune diseases, lymphoproliferative disorders, and several types of cancer, for the vast majority of infected people the infection is asymptomatic as EBV replication is controlled by the immune system. Immunity against this virus has been studied since the discovery of EBV in the 1960s, and although important insights have been made, no unbiased, global studies of immune responses to EBV in healthy seropositive subjects have been reported. Here we describe a novel protocol to study the cellular immune response to EBV, detecting lymphocytes that respond to EBV via analyses of proliferation or induced expression of activation markers and cytokines. Using this system we sequenced, for the first time at a single-cell level, the transcriptome of all cells capable of responding to EBV in healthy individuals and in patients with inborn errors of immunity (IEI) associated with susceptibility to EBV infection. Lymphocyte cytotoxicity appears to be crucial for the proper control of EBV-infection, while a proportionate T-regulatory cell response likely helps to avoid excessive immunity and immune pathology. We also show that γδ T cells expressing the TCR Vδ1 chain use various activating natural killer (NK) cell receptors to recognise and kill EBV-infected lymphoblastoid cell lines (LCLs) and thus could be a promising candidate for allogeneic cell therapy for EBV-associated lymphoproliferative disorders in patients with either primary or secondary immunodeficiencies.
- Open Access
The primary and secondary immune response to Epstein-Barr virus infection of human tonsil organoids
Epstein-Barr virus (EBV) is a human herpesvirus that causes acute infectious mononucleosis (IM) and is associated with cancer and autoimmune disease. Humans are the only natural host for EBV and humanised mice are the only small animal model of infection. Consequently, although IM in adults following primary infection has been studied intensively, little is known about the virological and immunological events that occur during the initial phases of the virus-host interaction. EBV is usually transmitted via saliva exchange, and is thought to infect its main host, the human B cell, in mucosal secondary lymphoid tissues, such as the tonsils. Thus, to address this gap in knowledge, we have studied the immune response to EBV infection using tonsil organoids as a model that allows us to address the greater systemic complexity present at the site of infection in the oropharynx. EBV infection is efficiently controlled when the tonsils are derived from “virus-experienced” individuals and CD8 + memory T lymphocytes expressing CD103 play a leading role in this immune response. In contrast, in primary infections, immune control of lymphoblastoid cell proliferation is much less effective, and a key factor restricting the immune response is the secretion of the immunomodulatory viral IL-10 molecule. These results highlight the importance of the host cytotoxic response at the site of infection and demonstrate that immune evasion molecules appear to be crucial for EBV-infected B cells to elude the local immune response and so disseminate the infection throughout the organism.
Open AccessThe primary and secondary immune response to Epstein-Barr virus infection of human tonsil organoids
Epstein-Barr virus (EBV) is a human herpesvirus that causes acute infectious mononucleosis (IM) and is associated with cancer and autoimmune disease. Humans are the only natural host for EBV and humanised mice are the only small animal model of infection. Consequently, although IM in adults following primary infection has been studied intensively, little is known about the virological and immunological events that occur during the initial phases of the virus-host interaction. EBV is usually transmitted via saliva exchange, and is thought to infect its main host, the human B cell, in mucosal secondary lymphoid tissues, such as the tonsils. Thus, to address this gap in knowledge, we have studied the immune response to EBV infection using tonsil organoids as a model that allows us to address the greater systemic complexity present at the site of infection in the oropharynx. EBV infection is efficiently controlled when the tonsils are derived from “virus-experienced” individuals and CD8 + memory T lymphocytes expressing CD103 play a leading role in this immune response. In contrast, in primary infections, immune control of lymphoblastoid cell proliferation is much less effective, and a key factor restricting the immune response is the secretion of the immunomodulatory viral IL-10 molecule. These results highlight the importance of the host cytotoxic response at the site of infection and demonstrate that immune evasion molecules appear to be crucial for EBV-infected B cells to elude the local immune response and so disseminate the infection throughout the organism.
- Open Access
A high-resolution, unbiased analysis of the cellular immune response to Epstein-Barr virus
More than 95% of humans are infected with Epstein-Barr virus (EBV), yet although EBV infection has been associated with inflammatory and autoimmune diseases, lymphoproliferative disorders, and several types of cancer, for the vast majority of infected people the infection is asymptomatic as EBV replication is controlled by the immune system. Immunity against this virus has been studied since the discovery of EBV in the 1960s, and although important insights have been made, no unbiased, global studies of immune responses to EBV in healthy seropositive subjects have been reported. Here we describe a novel protocol to study the cellular immune response to EBV, detecting lymphocytes that respond to EBV via analyses of proliferation or induced expression of activation markers and cytokines. Using this system we sequenced, for the first time at a single-cell level, the transcriptome of all cells capable of responding to EBV in healthy individuals and in patients with inborn errors of immunity (IEI) associated with susceptibility to EBV infection. Lymphocyte cytotoxicity appears to be crucial for the proper control of EBV-infection, while a proportionate T-regulatory cell response likely helps to avoid excessive immunity and immune pathology. We also show that γδ T cells expressing the TCR Vδ1 chain use various activating natural killer (NK) cell receptors to recognise and kill EBV-infected lymphoblastoid cell lines (LCLs) and thus could be a promising candidate for allogeneic cell therapy for EBV-associated lymphoproliferative disorders in patients with either primary or secondary immunodeficiencies. Graphical
Open AccessA high-resolution, unbiased analysis of the cellular immune response to Epstein-Barr virus
More than 95% of humans are infected with Epstein-Barr virus (EBV), yet although EBV infection has been associated with inflammatory and autoimmune diseases, lymphoproliferative disorders, and several types of cancer, for the vast majority of infected people the infection is asymptomatic as EBV replication is controlled by the immune system. Immunity against this virus has been studied since the discovery of EBV in the 1960s, and although important insights have been made, no unbiased, global studies of immune responses to EBV in healthy seropositive subjects have been reported. Here we describe a novel protocol to study the cellular immune response to EBV, detecting lymphocytes that respond to EBV via analyses of proliferation or induced expression of activation markers and cytokines. Using this system we sequenced, for the first time at a single-cell level, the transcriptome of all cells capable of responding to EBV in healthy individuals and in patients with inborn errors of immunity (IEI) associated with susceptibility to EBV infection. Lymphocyte cytotoxicity appears to be crucial for the proper control of EBV-infection, while a proportionate T-regulatory cell response likely helps to avoid excessive immunity and immune pathology. We also show that γδ T cells expressing the TCR Vδ1 chain use various activating natural killer (NK) cell receptors to recognise and kill EBV-infected lymphoblastoid cell lines (LCLs) and thus could be a promising candidate for allogeneic cell therapy for EBV-associated lymphoproliferative disorders in patients with either primary or secondary immunodeficiencies. Graphical
- Open Access
- 21 March 2024
- Published by Wiley in Immunology
- Vol. 172 (3) , 440-450
The lack of either IRF9, or STAT2, has surprisingly little effect on human natural killer cell development and function
Analysis of genetically defined immunodeficient patients allows study of the effect of the absence of specific proteins on human immune function in real‐world conditions. Here we have addressed the importance of type I interferon signalling for human NK cell development by studying the phenotype and function of circulating NK cells isolated from patients suffering primary immunodeficiency disease due to mutation of either the human interferon regulatory factor 9 (IRF9) or the signal transducer and activator of transcription 2 (STAT2) genes. IRF9, together with phosphorylated STAT1 and STAT2, form a heterotrimer called interferon stimulated gene factor 3 (ISGF3) which promotes the expression of hundreds of IFN‐stimulated genes that mediate antiviral function triggered by exposure to type I interferons. IRF9‐ and STAT2‐deficient patients are unable to respond efficiently to stimulation by type I interferons and so our experiments provide insights into the importance of type I interferon signalling and the consequences of its impairment on human NK cell biology. Surprisingly, the NK cells of these patients display essentially normal phenotype and function.
- 21 March 2024
- Published by Wiley in Immunology
- Vol. 172 (3) , 440-450
Open AccessThe lack of either IRF9, or STAT2, has surprisingly little effect on human natural killer cell development and function
Analysis of genetically defined immunodeficient patients allows study of the effect of the absence of specific proteins on human immune function in real‐world conditions. Here we have addressed the importance of type I interferon signalling for human NK cell development by studying the phenotype and function of circulating NK cells isolated from patients suffering primary immunodeficiency disease due to mutation of either the human interferon regulatory factor 9 (IRF9) or the signal transducer and activator of transcription 2 (STAT2) genes. IRF9, together with phosphorylated STAT1 and STAT2, form a heterotrimer called interferon stimulated gene factor 3 (ISGF3) which promotes the expression of hundreds of IFN‐stimulated genes that mediate antiviral function triggered by exposure to type I interferons. IRF9‐ and STAT2‐deficient patients are unable to respond efficiently to stimulation by type I interferons and so our experiments provide insights into the importance of type I interferon signalling and the consequences of its impairment on human NK cell biology. Surprisingly, the NK cells of these patients display essentially normal phenotype and function.
- Open Access
- 12 February 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1273942
Elevated levels of cell-free NKG2D-ligands modulate NKG2D surface expression and compromise NK cell function in severe COVID-19 disease
Introduction: It is now clear that coronavirus disease 19 (COVID-19) severity is associated with a dysregulated immune response, but the relative contributions of different immune cells is still not fully understood. SARS CoV-2 infection triggers marked changes in NK cell populations, but there are contradictory reports as to whether these effector lymphocytes play a protective or pathogenic role in immunity to SARS-CoV-2.Methods: To address this question we have analysed differences in the phenotype and function of NK cells in SARS-CoV-2 infected individuals who developed either very mild, or life-threatening COVID-19 disease.Results: Although NK cells from patients with severe disease appeared more activated and the frequency of adaptive NK cells was increased, they were less potent mediators of ADCC than NK cells from patients with mild disease. Further analysis of peripheral blood NK cells in these patients revealed that a population of NK cells that had lost expression of the activating receptor NKG2D were a feature of patients with severe disease and this correlated with elevated levels of cell free NKG2D ligands, especially ULBP2 and ULBP3 in the plasma of critically ill patients. In vitro, culture in NKG2DL containing patient sera reduced the ADCC function of healthy donor NK cells and this could be blocked by NKG2DL-specific antibodies.Discussion: These observations of reduced NK function in severe disease are consistent with the hypothesis that defects in immune surveillance by NK cells permit higher levels of viral replication, rather than that aberrant NK cell function contributes to immune system dysregulation and immunopathogenicity.
- 12 February 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1273942
Open AccessElevated levels of cell-free NKG2D-ligands modulate NKG2D surface expression and compromise NK cell function in severe COVID-19 disease
Introduction: It is now clear that coronavirus disease 19 (COVID-19) severity is associated with a dysregulated immune response, but the relative contributions of different immune cells is still not fully understood. SARS CoV-2 infection triggers marked changes in NK cell populations, but there are contradictory reports as to whether these effector lymphocytes play a protective or pathogenic role in immunity to SARS-CoV-2.Methods: To address this question we have analysed differences in the phenotype and function of NK cells in SARS-CoV-2 infected individuals who developed either very mild, or life-threatening COVID-19 disease.Results: Although NK cells from patients with severe disease appeared more activated and the frequency of adaptive NK cells was increased, they were less potent mediators of ADCC than NK cells from patients with mild disease. Further analysis of peripheral blood NK cells in these patients revealed that a population of NK cells that had lost expression of the activating receptor NKG2D were a feature of patients with severe disease and this correlated with elevated levels of cell free NKG2D ligands, especially ULBP2 and ULBP3 in the plasma of critically ill patients. In vitro, culture in NKG2DL containing patient sera reduced the ADCC function of healthy donor NK cells and this could be blocked by NKG2DL-specific antibodies.Discussion: These observations of reduced NK function in severe disease are consistent with the hypothesis that defects in immune surveillance by NK cells permit higher levels of viral replication, rather than that aberrant NK cell function contributes to immune system dysregulation and immunopathogenicity.
- Open Access
- 20 January 2024
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 115 (5) , 985-991
SARS-CoV-2 membrane protein-specific antibodies from critically ill SARS-CoV-2–infected individuals interact with Fc receptor–expressing cells but do not neutralize the virus
The membrane (M) glycoprotein of SARS-CoV-2 is one of the key viral proteins regulating virion assembly and morphogenesis. Immunologically, the M protein is a major source of peptide antigens driving T cell responses, and most individuals who have been infected with SARS-CoV-2 make antibodies to the N-terminal, surface-exposed peptide of the M protein. We now report that although the M protein is abundant in the viral particle, antibodies to the surface-exposed N-terminal epitope of M do not appear to neutralize the virus. M protein–specific antibodies do, however, activate antibody-dependent cell-mediated cytotoxicity and cytokine secretion by primary human natural killer cells. Interestingly, while patients with severe or mild disease make comparable levels of M antigen–binding antibodies, M-specific antibodies from the serum of critically ill patients are significantly more potent activators of antibody-dependent cell-mediated cytotoxicity than antibodies found in individuals with mild or asymptomatic infection.
- 20 January 2024
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 115 (5) , 985-991
Open AccessSARS-CoV-2 membrane protein-specific antibodies from critically ill SARS-CoV-2–infected individuals interact with Fc receptor–expressing cells but do not neutralize the virus
The membrane (M) glycoprotein of SARS-CoV-2 is one of the key viral proteins regulating virion assembly and morphogenesis. Immunologically, the M protein is a major source of peptide antigens driving T cell responses, and most individuals who have been infected with SARS-CoV-2 make antibodies to the N-terminal, surface-exposed peptide of the M protein. We now report that although the M protein is abundant in the viral particle, antibodies to the surface-exposed N-terminal epitope of M do not appear to neutralize the virus. M protein–specific antibodies do, however, activate antibody-dependent cell-mediated cytotoxicity and cytokine secretion by primary human natural killer cells. Interestingly, while patients with severe or mild disease make comparable levels of M antigen–binding antibodies, M-specific antibodies from the serum of critically ill patients are significantly more potent activators of antibody-dependent cell-mediated cytotoxicity than antibodies found in individuals with mild or asymptomatic infection.
- Open Access
- 25 September 2023
- Published by Springer Nature in Research Square
Cell therapy could benefit from BCG: how anti-tumour BCG-primed NK cells selectively proliferate over other lymphocytes and efficiently kill cancer cells
Natural killer (NK) cell-based immunotherapies are safe, promising treatments for patients with cancer. Nevertheless, the short-lived nature of NK cells, the heterogeneity of NK populations and the need to infuse large number of cells for efficient tumour elimination represent important challenges for the development of NK cell-based therapies. Therefore, improved approaches to produce high numbers of long-lived, cytotoxic NK cells are essential for clinical applications. We have previously identified anti-tumour NK cells (CD56highCD16+NKG2A+) generated upon exposure to Bacillus Calmette-Guérin (BCG), an early immunotherapy that has been used for decades to treat bladder cancer. Here, we describe that BCG-primed NK cells (B-pNK) kill a broad range of solid tumours and specifically proliferate, without the need of cell sorting, by weekly stimulations with low doses of cytokines, while BCG and other peripheral blood mononuclear cells decrease in the culture. In depth scRNA-seq analysis showed that B-pNK upregulated IL12, IL15 or IL21 signalling pathways, but not IL18, according to the Reactome database. Consequently, B-pNK cells potently proliferated and enriched over other lymphocytes, after weekly stimulations with this cytokine combination, used in low concentration to avoid overstimulation. Despite NKG2A expression, B-pNK mediated potent anti-tumour activity as demonstrated in functional assays, including degranulation, specific cytotoxicity and intracellular-cytokine release, being NKG2D the main activating receptor involved in tumour recognition and elimination. We propose that a strategy based on BCG-priming of NK cells provides a scalable and economical approach for the development of safe and universal cellular immunotherapies against solid tumours.
- 25 September 2023
- Published by Springer Nature in Research Square
Open AccessCell therapy could benefit from BCG: how anti-tumour BCG-primed NK cells selectively proliferate over other lymphocytes and efficiently kill cancer cells
Natural killer (NK) cell-based immunotherapies are safe, promising treatments for patients with cancer. Nevertheless, the short-lived nature of NK cells, the heterogeneity of NK populations and the need to infuse large number of cells for efficient tumour elimination represent important challenges for the development of NK cell-based therapies. Therefore, improved approaches to produce high numbers of long-lived, cytotoxic NK cells are essential for clinical applications. We have previously identified anti-tumour NK cells (CD56highCD16+NKG2A+) generated upon exposure to Bacillus Calmette-Guérin (BCG), an early immunotherapy that has been used for decades to treat bladder cancer. Here, we describe that BCG-primed NK cells (B-pNK) kill a broad range of solid tumours and specifically proliferate, without the need of cell sorting, by weekly stimulations with low doses of cytokines, while BCG and other peripheral blood mononuclear cells decrease in the culture. In depth scRNA-seq analysis showed that B-pNK upregulated IL12, IL15 or IL21 signalling pathways, but not IL18, according to the Reactome database. Consequently, B-pNK cells potently proliferated and enriched over other lymphocytes, after weekly stimulations with this cytokine combination, used in low concentration to avoid overstimulation. Despite NKG2A expression, B-pNK mediated potent anti-tumour activity as demonstrated in functional assays, including degranulation, specific cytotoxicity and intracellular-cytokine release, being NKG2D the main activating receptor involved in tumour recognition and elimination. We propose that a strategy based on BCG-priming of NK cells provides a scalable and economical approach for the development of safe and universal cellular immunotherapies against solid tumours.
- Open Access
- 5 April 2022
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 112 (2) , 339-346
Cross-reactive cellular, but not humoral, immunity is detected between OC43 and SARS-CoV-2 NPs in people not infected with SARS-CoV-2: Possible role of cTFH cells
Multiple questions about SARS-CoV-2 humoral and cellular immunity remain unanswered. One key question is whether preexisting memory T or B cells, specific for related coronaviruses in SARS-CoV-2-unexposed individuals, can recognize and suppress COVID-19, but this issue remains unclear. Here, we demonstrate that antibody responses to SARS-CoV-2 antigens are restricted to serum samples from COVID-19 convalescent individuals. In contrast, cross-reactive T cell proliferation and IFN-γ production responses were detected in PBMCs of around 30% of donor samples collected prepandemic, although we found that these prepandemic T cell responses only elicited weak cTFH activation upon stimulation with either HCoV-OC43 or SARS-CoV-2 NP protein. Overall, these observations confirm that T cell cross-reactive with SARS-CoV-2 antigens are present in unexposed people, but suggest that the T cell response to HCoV-OC43 could be deficient in some important aspects, like TFH expansion, that might compromise the generation of cross-reactive TFH cells and antibodies. Understanding these differences in cellular responses may be of critical importance to advance in our knowledge of immunity against SARS-CoV-2.
- 5 April 2022
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 112 (2) , 339-346
Open AccessCross-reactive cellular, but not humoral, immunity is detected between OC43 and SARS-CoV-2 NPs in people not infected with SARS-CoV-2: Possible role of cTFH cells
Multiple questions about SARS-CoV-2 humoral and cellular immunity remain unanswered. One key question is whether preexisting memory T or B cells, specific for related coronaviruses in SARS-CoV-2-unexposed individuals, can recognize and suppress COVID-19, but this issue remains unclear. Here, we demonstrate that antibody responses to SARS-CoV-2 antigens are restricted to serum samples from COVID-19 convalescent individuals. In contrast, cross-reactive T cell proliferation and IFN-γ production responses were detected in PBMCs of around 30% of donor samples collected prepandemic, although we found that these prepandemic T cell responses only elicited weak cTFH activation upon stimulation with either HCoV-OC43 or SARS-CoV-2 NP protein. Overall, these observations confirm that T cell cross-reactive with SARS-CoV-2 antigens are present in unexposed people, but suggest that the T cell response to HCoV-OC43 could be deficient in some important aspects, like TFH expansion, that might compromise the generation of cross-reactive TFH cells and antibodies. Understanding these differences in cellular responses may be of critical importance to advance in our knowledge of immunity against SARS-CoV-2.
- Open Access
Natural killer (NK) cell-derived extracellular-vesicle shuttled microRNAs control T cell responses
Natural killer (NK) cells recognise and kill target cells undergoing different types of stress. NK cells are also capable of modulating immune responses. In particular, they regulate T cell functions. Small RNA next-generation sequencing of resting and activated NK cells and their secreted EVs led to the identification of a specific repertoire of NK-EV-associated microRNAs and their post-transcriptional modifications signature. Several microRNAs of NK-EVs, namely miR-10b-5p, miR-92a-3p and miR-155-5p, specifically target molecules involved in Th1 responses. NK-EVs promote the downregulation of GATA-3 mRNA in CD4 + T cells and subsequent T-bet de-repression that leads to Th1 polarization and IFN-γ and IL-2 production. NK-EVs also have an effect on monocyte and moDCs function, driving their activation and increased presentation and co-stimulatory functions. Nanoparticle-delivered NK-EV microRNAs partially recapitulate NK-EV effects in vivo . Our results provide new insights on the immunomodulatory roles of NK-EVs that may help to improve their use as immunotherapeutic tools.
Open AccessNatural killer (NK) cell-derived extracellular-vesicle shuttled microRNAs control T cell responses
Natural killer (NK) cells recognise and kill target cells undergoing different types of stress. NK cells are also capable of modulating immune responses. In particular, they regulate T cell functions. Small RNA next-generation sequencing of resting and activated NK cells and their secreted EVs led to the identification of a specific repertoire of NK-EV-associated microRNAs and their post-transcriptional modifications signature. Several microRNAs of NK-EVs, namely miR-10b-5p, miR-92a-3p and miR-155-5p, specifically target molecules involved in Th1 responses. NK-EVs promote the downregulation of GATA-3 mRNA in CD4 + T cells and subsequent T-bet de-repression that leads to Th1 polarization and IFN-γ and IL-2 production. NK-EVs also have an effect on monocyte and moDCs function, driving their activation and increased presentation and co-stimulatory functions. Nanoparticle-delivered NK-EV microRNAs partially recapitulate NK-EV effects in vivo . Our results provide new insights on the immunomodulatory roles of NK-EVs that may help to improve their use as immunotherapeutic tools.